
Mira Pharmaceuticals (MIRA) Stock
Small drug developer focused on early clinical trials. Here's the price, business snapshot, and what's worth knowing about Mira Pharmaceuticals in November 2026.
Mira Pharmaceuticals Inc (ticker MIRA) is a micro‑cap biotechnology company with a market capitalisation of about $27.65 million. It focuses on early‑stage therapeutic programmes, where value is typically driven by clinical data, regulatory milestones and commercial partnerships. As a small biotech, Mira may have limited revenues and a shorter cash runway compared with larger peers, making financing rounds and partnership agreements important potential catalysts. Investors should be aware that outcomes in clinical development are uncertain: positive trial results can meaningfully re-rate a stock, while setbacks or delays can have the opposite effect. Liquidity can be low and shares may be highly volatile. Due diligence should include reading regulatory filings, investor presentations and peer‑reviewed data where available. This summary is educational only and not personalised financial advice; consider your risk tolerance and consult a regulated adviser before making investment decisions.
Mira Pharmaceuticals (MIRA) Stock Forecast
Analyst price target, next 12 months
$3.00
+354.6% vs today's $0.66
Price range over the last 12 months
Close to its 12-month low
Analysts covering Mira Pharmaceuticals have a consensus 12-month target of $3.00, above the current price of $0.66.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 28 Oct 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Six-Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts strongly recommend buying MIRA Pharmaceuticals' stock, anticipating significant price growth ahead.
Financial Health
Mira Pharmaceuticals has steady cash flow and book value, indicating stable financial performance.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Clinical Milestones Ahead
Trial readouts and regulatory progress can drive significant share moves, though outcomes are uncertain and delays common.
Funding & Dilution
Small biotechs frequently need to raise capital; fundraising terms can dilute existing shareholders and affect timelines.
Partnering Potential
Licensing or collaboration deals may validate programmes and reduce execution risk, but depend on data and negotiation outcomes.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.